Slide 1: Q3 2024 Earnings Call
Q3 2024 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO November 21, 2024
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are co
Slide 3: Agenda
Earnings Call Q3 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements Q&A 3 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 4: CEO Update Q3 Financial highlights
4 4 CEO Update Q3 Financial highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million compared to $5.1 million in the first nine months 2023. In Q3 of 2024, total revenues reached approximately $1.8 million, compared to $3.8 million in Q3 2023. The revenues in Q
Slide 5: CEO Update Q3 Financial highlights: financing expenses and cash usage
5 5 CEO Update Q3 Financial highlights: In the first nine months of 2024, financing expenses net, were approximately $0.38 million, compared to financing income of $0.23 million in the first 9-months of 2023. The financing expenses in the first nine months of 2024 net, included $0.88 million expense
Slide 6: CEO Update Q3 Business Highlights
6 6 CEO Update Q3 Business Highlights: Evogene Collaboration with Google Cloud to pioneer generative AI foundation model for novel small molecule design. Second year grant approval received from Israel Innovation Authority to continue collaboration with Watershed AC (formerly Colors Farm) & BGU, foc
Slide 7: Q3 Business Highlights: Lavie Bio, AgPlenus, Biomica
Q3 Business Highlights: Lavie Bio Commercial expansion of Yalos® to winter wheat (July) and at present (November) to soybean. Spring 2025, expected initial sales for soybean. Advancement of LAV321, a bio-fungicide targeting downy mildew, to pre-commercialization, following successful field trial res
Slide 8: Agenda: Evogene Overview
Earnings Call Q3 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements Q&A 8 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 9: Our Vision
OUR VISION PIONEER GROUNDBREAKING LIFE-SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS DECODING BIOLOGY 9
Slide 10: Discovery & Optimization with 3 AI tech-engines
DISCOVERY & OPTIMIZATION WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT through 3 dedicated AI tech-engines MICROBES GENETIC ELEMENTS SMALL MOLECULES The Result: Promising candidates addressing multiple development challenges towards successful life-science-based products. PROBABILITY OF SUCCESS TIME
Slide 11: Collaboration with Google Cloud
11 COLLABORATION with Google Cloud Oct. 31 - Collaboration with Google Cloud to pioneer generative AI foundation model for novel small molecule design. The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products
Slide 12: A World of Opportunities for Our AI Tech Engines
12 SMALL MOLECULES GENETIC ELEMENTS MICROBES A WORLD OF OPPORTUNITIES FOR OUR AI TECH ENGINES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Improvedcrops Alternativefood Medical Cannabis Genetherapy Diagnostics & precisionmedicine Celltherapy Bio fuel Fragrances Natural foodcoloring Novelenz
Slide 13: Business Strategy
13 BUSINESS STRATEGY Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene. EVOGENE
Slide 14: Licensing & Collaboration: Current Status
Aquaculture Licensing Collaboration Improved crops Crop protection Pharmaceuticals Microbials for crops Therapeutic microbials 14 LICENSING & COLLABORATION | CURRENT STATUS Food-Tech AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES AGRICULTU
Slide 15: Evogene Collaborations
October 8 - Watershed AC (formerly Colors Farm), Evogene and Ben-Gurion University received approval for second year grant to continue the collaboration focused on improving crustacean traits utilizing gene editing technology. EVOGENE COLLABORATIONS Efforts to advance collaborations with companies f
Slide 16: Commercial & Financial Partners
16 Group COMMERCIAL & FINANCIAL PARTNERS Investment & Collaboration Collaboration Investment & Collaboration Collaboration Collaboration Investment Collaboration Collaboration Collaboration Collaboration Collaboration
Slide 17: Agenda: Subsidiaries' Achievements
Earnings Call Q3 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements Q&A 17 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 18: Casterra
18 Casterra focuses on developing integrated solutions for large-scale castor bean cultivation, utilizing GeneRator AI tech-engine July 31 - Successfully completed castor seed growing and harvesting season in Brazil with shipments planned to be initiated starting Q3 2024. Oct. 29 - Achieving key mil
Slide 19: Lavie Bio
19 Lavie Bio, a global leader in developing next generation ag-biological products, leveraging MicroBoost AI tech-engine July 2 - Commercial expansion of Yalos® to winter wheat. Initial sales to growers started in Q3 2024. July 17 - ICL and Lavie Bio announced a milestone in developing bio-stimulant
Slide 20: AgPlenus
AgPlenus specializes in developing novel and sustainable crop protection products, utilizing Evogene’s ChemPass AI tech-engine Collaborations: Bayer and Corteva collaborations advancing according to plan. Pipeline: Septoria, novel fungicide program - 3 out of 3 predicted proteins have been verified
Slide 21: Biomica
21 Biomica specializes in developing microbiome-based therapeutics for human health, utilizing Evogene's MicroBoost AI tech-engine BMC128 continued phase I clinical study, with prolonged positive response of 5 patients. Pre IND meeting with positive feedback from the FDA, and preparation for IND sub
Slide 22: Agenda: CFO Update
Earnings Call Q3 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements Q&A 22 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 23: CFO Update: Balance Sheet
CFO UPDATE CURRENT ASSETS: ‘Cash and cash equivalents ‘Short-term bank deposits Trade receivables Other receivables and prepaid expenses Inventories LONG-TERM ASSETS: ‘Long-term deposits and other receivables Investment accounted for sing the equity method Right-of-use-assets Property, plant and equ
Slide 24: CFO Update: Evogene Financial Performance Q3 2024
CFO UPDATE Evogene Financial Performance Q3 2024 24
Slide 25: Agenda: Q&A
Earnings Call Q3 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements Q&A 25 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 26: Thank You
} THANK YOU 5)